Monoclonal antibody (mAb) manufacturers struggling with single-use technology (SUT)-derived impurities should use ultrafiltration and diafiltration as the basis of their…
The strategies biopharmaceutical manufacturers currently use to limit protein misfolding are complex, time-consuming, and generate low yields with only limited…